|1.||Channon, Keith M: 26 articles (06/2015 - 03/2004)|
|2.||Blau, Nenad: 24 articles (03/2015 - 02/2002)|
|3.||Blau, N: 12 articles (12/2009 - 01/2000)|
|4.||Alp, Nicholas J: 10 articles (10/2011 - 03/2004)|
|5.||Muntau, Ania C: 8 articles (03/2015 - 12/2002)|
|6.||Thöny, Beat: 8 articles (02/2011 - 01/2004)|
|7.||Desviat, Lourdes R: 7 articles (03/2015 - 11/2004)|
|8.||Feillet, François: 7 articles (03/2015 - 08/2007)|
|9.||Trefz, Friedrich K: 7 articles (01/2015 - 02/2002)|
|10.||Moens, An L: 7 articles (01/2012 - 11/2006)|
01/01/2009 - "Use of tetrahydrobiopterin is a new, alternative treatment method, effective in some phenylketonuria-patients. "
11/15/2008 - "Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria."
03/01/2015 - "To our knowledge this is the largest study using algorithms for the prediction of patients' phenotype and tetrahydrobiopterin responsiveness in phenylketonuria patients, using data from the locus-specific and genotypes database."
01/01/2015 - "The Kuvan(®) Adult Maternal Paediatric European Registry (KAMPER) Multinational Observational Study: Baseline and 1-Year Data in Phenylketonuria Patients Responsive to Sapropterin."
05/01/2013 - "The aim of this study was to identify the most common genotypes in the phenylketonuria (PKU) population of Andalusia, assessing the correlation with the phenotype and the usefulness in predicting the response to treatment with tetrahydrobiopterin. "
08/01/2012 - "Tetrahydrobiopterin ameliorates hepatic ischemia-reperfusion Injury by coupling with eNOS in mice."
06/01/2002 - "Hearts from tetrahydrobiopterin-treated rats exhibited protection against ischemia-reperfusion injury (left ventricular developed pressure: 74 +/- 4 vs control 42 +/- 8 mm Hg, P =.01; left ventricular end-diastolic pressure: 12 +/- 3 vs 34 +/- 7 mm Hg, P =.01). "
10/01/2002 - "The aim of this study was to clarify whether supplement with tetrahydrobiopterin would exert a cardioprotective effect against ischemia-reperfusion injury. "
10/01/2012 - "Tetrahydrobiopterin has been shown to efficiently abrogate ischemia reperfusion injury (IRI). "
10/01/2012 - "Prevention of lethal murine pancreas ischemia reperfusion injury is specific for tetrahydrobiopterin."
10/31/2000 - "Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis."
10/01/2000 - "Because endothelial dysfunction has been implicated in the development of graft failure, studies aimed at chronic delivery of tetrahydrobiopterin would be useful in determining the contribution of this cofactor toward saphenous vein atherosclerosis."
04/01/2007 - "Although it has been reported that oral administration of tetrahydrobiopterin (BH4) prevents endothelial dysfunction and vascular oxidative stress in various rat models, the effect of treatment with BH4 on atherogenesis remains unclear. "
09/30/2008 - "CCR2-mediated antiinflammatory effects of endothelial tetrahydrobiopterin inhibit vascular injury-induced accelerated atherosclerosis."
03/01/2004 - "Tetrahydrobiopterin (BH4) is a required cofactor for NO synthesis by endothelial nitric oxide synthase (eNOS); pharmacologic studies suggest that reduced BH4 availability may be an important mediator of endothelial dysfunction in atherosclerosis. "
11/01/2012 - "Restoring proper NOS activity by increasing intracellular levels of its cofactor tetrahydrobiopterin (BH4) is effective in the management of hypertensive diastolic dysfunction, ischemia-reperfusion injury, myocardial infarction and endothelial dysfunction. "
02/01/2006 - "This study examined whether intravenous administration of tetrahydrobiopterin (BH4) reduces myocardial infarct size following ischemia/reperfusion (I/R) in rats, and the mechanisms of its protective effect were also investigated. "
05/01/2010 - "The goal of this study was to elucidate whether there is an increase in myocardial tetrahydrobiopterin (BH4), which is a cofactor for nitric oxide synthase, during the late phase of ischaemic preconditioning (IPC) leading to cardioprotection against myocardial infarction and, if so, to examine the induction mechanisms of BH4 synthesis. "
09/01/2008 - "Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: the possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase."
01/01/2007 - "Changes of asymmetric dimethylarginine, nitric oxide, tetrahydrobiopterin, and oxidative stress in patients with acute myocardial infarction by medical treatments."
07/01/2006 - "The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis."
10/01/2011 - "In a dose range of 36-200mg/kg/d, 6R-BH4 suppressed cardiac chamber remodeling, hypertrophy, fibrosis, and oxidative stress with pressure-overload. "
05/20/2008 - "We tested whether tetrahydrobiopterin (BH4) can recouple NOS and reverse preestablished advanced hypertrophy, fibrosis, and dysfunction. "
07/01/2006 - "Tetrahydrobiopterin supplementation increased BH4 hepatic levels and eNOS activity and significantly improved the vasodilator response to acetylcholine in rats with cirrhosis. "
08/01/2008 - "Tetrahydrobiopterin is an essential cofactor for NOS enzymes to synthesize NO. It has been suggested that reduced intrahepatic tetrahydrobiopterin decreases intrahepatic NO and contributes to increase hepatic vascular resistance and portal pressure in cirrhosis. "
|2.||Nitric Oxide (Nitrogen Monoxide)
|3.||Nitric Oxide Synthase (NO Synthase)
|5.||Acetylcholine (Acetylcholine Chloride)
|6.||GTP Cyclohydrolase (GTP Cyclohydrolase I)
|8.||Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)
|9.||Phenylalanine Hydroxylase (Phenylalanine 4 Monooxygenase)
|10.||Guanosine Triphosphate (GTP)
|5.||Homologous Transplantation (Allograft)